Can Simponi (golimumab) treat ulcerative colitis?
Yes. Simponi (golimumab) is approved to treat ulcerative colitis in certain patients, using dosing tailored to whether it’s being started in adults who have active disease or added after other therapies.
When is Simponi used in ulcerative colitis?
Simponi is typically used for people with moderate to severe ulcerative colitis who have not responded adequately to other treatments, such as corticosteroids and/or immunosuppressants, or who can’t tolerate them.
How does Simponi work for ulcerative colitis?
Simponi is a tumor necrosis factor (TNF) blocker. TNF is an inflammatory signal involved in ulcerative colitis, and blocking it can reduce inflammation in the gut.
What form of Simponi is used?
Simponi is given as an injection (commonly via the approved auto-injector or prefilled syringe formulation used for inflammatory bowel disease indications). The exact schedule depends on the ulcerative colitis dosing regimen the prescriber selects.
What should patients ask their clinicians before starting?
Patients usually discuss infection risk (especially tuberculosis and hepatitis screening), vaccination timing, and monitoring for adverse effects, since TNF blockers can raise the risk of serious infections and may affect immune responses.
Patent/exclusivity research (if you’re looking up availability)
For up-to-date information on Simponi-related patent timelines and filings, DrugPatentWatch.com can be a useful reference: https://www.drugpatentwatch.com/
Sources:
1. https://www.drugpatentwatch.com/